Colistin versus meropenem in the empirical treatment of ventilator-associated pneumonia (Magic Bullet study): an investigator-driven, open-label, randomized, noninferiority controlled trial

Colistin versus meropenem in the empirical treatment of ventilator-associated pneumonia (Magic Bullet study): an investigator-driven, open-label, randomized, noninferiority controlled trial

Abstract Background Colistin is recommended in the empirical treatment of ventilator-associated pneumonia (VAP) with a high prevalence of carbapenem-resistant gram-negative bacilli (CR-GNB). However, the efficacy and safety of colistin are not well defined. Methods A multicenter prospective randomiz...

Full description

Bibliographic Details
Main Authors: José M. Cisneros, Clara María Rosso-Fernández, Cristina Roca-Oporto, Gennaro De Pascale, Silvia Jiménez-Jorge, Esteban Fernández-Hinojosa, Dimitrios K. Matthaiou, Paula Ramírez, Ramón Ortiz Díaz-Miguel, Angel Estella, Massimo Antonelli, George Dimopoulos, José Garnacho-Montero, on behalf of the Magic Bullet Working Group WP1
Format: Article
Language:English
Published: BMC 2019-11-01
Series:Critical Care
Subjects:
Colistin
Ventilator-associated pneumonia
Multidrug-resistant bacteria
Carbapenem-resistant gram-negative bacilli
Online Access:https://doi.org/10.1186/s13054-019-2627-y

Internet

https://doi.org/10.1186/s13054-019-2627-y

Similar Items